Travere Therapeutics Analysis

Travere Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Travere Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Travere Therapeutics is worth, separate from its market price. There are two main types of Travere Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Travere Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Travere Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Travere Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Travere Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Travere Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Travere Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Travere Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The book value of Travere Therapeutics was at this time reported as 5.91. The company recorded a loss per share of 1.72. Travere Therapeutics had not issued any dividends in recent years. The entity had 1:9 split on the 8th of November 2011. Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California. Retrophin operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 221 people. To find out more about Travere Therapeutics contact Eric Dube at 888 969-7879 or learn more at www.retrophin.com.

Travere Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Travere Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Travere Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Travere Therapeutics is not yet fully synchronised with the market data
Travere Therapeutics has some characteristics of a very speculative penny stock
Travere Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 194.02 M. Net Loss for the year was (78.07 M) with profit before overhead, payroll, taxes, and interest of 170.1 M.
Travere Therapeutics currently holds about 456.27 M in cash with (33.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94.
Over 99.0% of the company shares are owned by institutional investors

Travere Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.24 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Travere Therapeutics's market, we take the total number of its shares issued and multiply it by Travere Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Travere Profitablity

Travere Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Travere Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Travere Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Travere Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Travere Therapeutics' profitability requires more research than a typical breakdown of Travere Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (40.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (35.61) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $35.61.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Travere Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Dashboard Now

   

Portfolio Dashboard

Portfolio dashboard that provides centralized access to all your investments
All  Next Launch Module
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Travere Stock

If you are still planning to invest in Travere Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Travere Therapeutics' history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
AI Investment Finder
Use AI to screen and filter profitable investment opportunities